Blood biomarkers of stroke

Patent metadata

Field	Value
Publication number	US-12247257-B2
Application number	US-201917054820-A
Country	US
Kind code	B2
Filing date	May 16, 2019
Priority date	May 16, 2018
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

A method of diagnosing a stroke, a method of determining whether a subject suffering from a stroke will achieve a response with a therapy, a method of determining whether a subject is at risk of having a stroke, and a method for treating a stroke in a subject, by determining a signature in a sample obtained from the subject by measuring the expression levels of at least two biomarkers selected from the group consisting of PTGS2, HMOX1, LDLR, HSPA1B, G0S2, BAG3, TM4SF1, DUSP1 and ADM are provided.

First claim

The invention claimed is:

1. A method for eliminating or reducing the symptoms of a stroke, for slowing or eliminating the progression of a stroke, and/or for delaying the initial occurrence or the reoccurrence of a stroke, in a human or a non-human primate subject identified as being affected by stroke or as being at risk of having a stroke, comprising:
a. identifying the subject as being affected with a stroke or as being at risk of having a stroke by:
i) determining a signature in a sample obtained from the subject by measuring the expression levels of at least three biomarkers selected from the group consisting of PTGS2, HMOX1, LDLR, HSPA1B, G0S2, BAG3, TM4SF1, DUSP1 and ADM wherein the sample is a blood sample, a plasma sample, a serum sample, or a saliva sample;
ii) comparing the signature determined in step i) with a reference signature;
iii) identifying the subject with the expression levels of the at least three biomarkers in the signature are higher than the expression levels of the same at least three biomarkers in the reference signature as being affected with a stroke or as being at risk of having a stroke; and
b. administering thrombectomy, antithrombotic agents, anticoagulants, antiplatelet drugs, thrombolytic drugs, a neuroprotective agent, hypothermia, or a combination thereof, to treating or preventing the stroke in the subject identified as being affected with a stroke or as being at risk of having a stroke.

2. The method according to claim 1 , wherein step i) comprises measuring the expression levels of PTGS2, HMOX1, LDLR, HSPA1B, G0S2, BAG3, TM4SF1, DUSP1 and ADM.

3. The method according to claim 1 , wherein the reference signature is obtained by measuring the expression levels of the biomarkers in a reference population of substantially healthy subjects.

4. The method according to claim 1 , wherein stroke is ischemic stroke, transient ischemic attack or a hemorrhagic stroke.

5. The method according to claim 1 , wherein the subject has experienced a stroke and is at risk of having a recurrent stroke.

6. The method according to claim 1 , wherein the signature enables for distinguishing a stroke from a stroke mimic.

Assignees

• Centre Hospitalier Regional Et Univ De Brest
• Francais Du Sang Ets
• Inst Nat Sante Rech Med
• Univ Bretagne Occidentale
• Etablisssement Francais Du Sang
• Inserm Institut National De La Santeet De La Rech Medicale

Inventors

• Timsit Serge
• Genin Emmanuelle

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title